Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:70004 |
Name | myeloid neoplasm |
Definition | A bone marrow cancer that is formed of any one of the bone marrow cells belonging to the granulocytic (neutrophil, eosinophil, basophil), monocytic/macrophage, erythroid, megakaryocytic and mast cell lineages. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
FGFR3 K650E FGFR3 over exp HRAS K117E | AZ8010 | myeloid neoplasm | sensitive | detail... |
FGFR3 wild-type | SSR128129E | myeloid neoplasm | sensitive | detail... |
FGFR3 K650E | SSR128129E | myeloid neoplasm | no benefit | detail... |
FGFR3 Y373C | Zoligratinib | myeloid neoplasm | sensitive | detail... |
FGFR3 K650E | Zoligratinib | myeloid neoplasm | sensitive | detail... |
FGFR3 F386L | Zoligratinib | myeloid neoplasm | sensitive | detail... |
FGFR3 wild-type | SU5402 | myeloid neoplasm | sensitive | detail... |
FGFR3 K650E | SU5402 | myeloid neoplasm | sensitive | detail... |
FGFR3 rearrange | PRN1371 | myeloid neoplasm | sensitive | detail... |
FGFR3 Y373C | RO4987655 | myeloid neoplasm | no benefit | detail... |
FGFR3 Y373C | RO5126766 | myeloid neoplasm | no benefit | detail... |
FGFR3 Y373C | Selumetinib | myeloid neoplasm | no benefit | detail... |
FGFR3 rearrange | Fexagratinib | myeloid neoplasm | sensitive | detail... |
IDH1 mutant | Ivosidenib + Venetoclax | myeloid neoplasm | predicted - sensitive | detail... |
IDH1 mutant | Azacitidine + Ivosidenib + Venetoclax | myeloid neoplasm | predicted - sensitive | detail... |
JAK2 rearrange | Ruxolitinib | myeloid neoplasm | sensitive | detail... |
JAK2 rearrange | Fedratinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Dasatinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Nilotinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Imatinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Bosutinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Ponatinib | myeloid neoplasm | sensitive | detail... |
FLT3 rearrange | Gilteritinib | myeloid neoplasm | sensitive | detail... |
FLT3 rearrange | Midostaurin | myeloid neoplasm | sensitive | detail... |
FLT3 rearrange | Sorafenib | myeloid neoplasm | sensitive | detail... |
FLT3 rearrange | Sunitinib | myeloid neoplasm | sensitive | detail... |
ABL1 rearrange | Asciminib | myeloid neoplasm | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01885897 | Phase Ib/II | Nogapendekin alfa inbakicept | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | Completed | USA | 0 |
NCT02420860 | Phase II | Famotidine Elotuzumab + Lenalidomide Diphenhydramine Dexamethasone | Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT) | Active, not recruiting | USA | 0 |
NCT02506959 | Phase II | Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma | Completed | USA | 0 |
NCT02843074 | Phase II | Dexamethasone + Elotuzumab + Lenalidomide | Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients | Completed | USA | 0 |
NCT02969837 | Phase II | Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide | Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03503968 | Phase Ib/II | MDG1011 | TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms | Terminated | DEU | 0 |
NCT03531918 | Phase Ib/II | Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin + Mitoxantrone Cladribine + Cytarabine + Filgrastim | Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm | Completed | USA | 0 |
NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04189445 | Phase II | Futibatinib | Futibatinib in Patients With Specific FGFR Aberrations | Active, not recruiting | USA | TUR | SWE | NLD | ITA | GBR | FRA | ESP | DEU | BEL | 5 |
NCT04195945 | Phase II | CPX-351 Cladribine + Cytarabine + Filgrastim + Mitoxantrone | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | Recruiting | USA | 0 |
NCT04797767 | Phase I | Cladribine + Cytarabine + Mitoxantrone + Sargramostim + Venetoclax | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | Suspended | USA | 0 |